Tysabri scores positive results in Crohn's trial

Elan and partner Biogen Idec say that a Phase III trial of Tysabri produced positive results for patients with Crohn's disease, an inflammation of the gastrointestinal system. The results for the 510-patient study showed a reduction in symptoms after 12 weeks of treatment. That news produced only a modest uptick in Elan's stock, though, which has been hammered since the two companies removed Tysabri from the market after it was linked to two cases of the rare brain disease PML. Since then, two newspapers have reported additional possible cases of PML. Elan and Biogen Idec have steadfastly maintained that they can develop a strategy to get the drug safely back on the market and said they would submit the latest trial results to the FDA for its consideration.

- read this article from the AP for more

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.